Phase II open-label, sequential cohort, dose-escalation study of BMN 111 in children with achondroplasia

Trial Profile

Phase II open-label, sequential cohort, dose-escalation study of BMN 111 in children with achondroplasia

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs Vosoritide (Primary)
  • Indications Achondroplasia
  • Focus Adverse reactions; Proof of concept
  • Acronyms ACH
  • Sponsors BioMarin Pharmaceutical
  • Most Recent Events

    • 19 May 2017 Planned End Date changed from 1 Jan 2019 to 1 Dec 2017.
    • 19 May 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Nov 2017.
    • 19 May 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top